Recent advances in metabolomics analysis for early drug development

Juan Carlos Alarcón; Sarantos Kostidis; Alejandro Ondo-Méndez; Martin  Giera

doi:10.1016/j.drudis.2022.02.018

Recent advances in metabolomics analysis for early drug development

Título traducido de la contribución: Avances recientes en análisis metabolómico para el desarrollo temprano de medicamentos

Juan Carlos Alarcón, Sarantos Kostidis, Alejandro Ondo-Méndez, Martin Giera

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

57 Citas (Scopus)

Resumen

La industria farmacéutica adaptó la proteómica y otras tecnologías 'ómicas para la investigación de medicamentos poco después de su introducción inicial. Aunque la metabolómica se retrasó en este desarrollo, ahora se ha convertido en un enfoque aceptado y ampliamente aplicado en el desarrollo temprano de medicamentos. Durante las últimas décadas, la metabolómica ha evolucionado de ser una herramienta puramente exploratoria a una tecnología bioquímica más madura y cuantitativa. Varias plataformas basadas en metabolómica se aplican ahora durante las primeras fases del descubrimiento de medicamentos. El análisis metabolómico ayuda en la definición de la respuesta fisiológica y los marcadores de compromiso de objetivo (TE, por sus siglas en inglés) así como en la elucidación del modo de acción (MoA) de los candidatos a medicamentos bajo investigación. En esta revisión, destacamos ejemplos recientes y nuevos desarrollos de análisis metabolómicos aplicados durante el desarrollo temprano de medicamentos.

Título traducido de la contribución	Avances recientes en análisis metabolómico para el desarrollo temprano de medicamentos
Idioma original	Inglés estadounidense
Publicación	Drug Discovery Today
Fecha en línea anticipada	feb. 24 2022
DOI	https://doi.org/10.1016/j.drudis.2022.02.018 https://doi.org/10.1016/j.drudis.2022.02.018
Estado	Publicada - feb. 24 2022

Áreas temáticas de ASJC Scopus

Medicina molecular

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

Citar esto

@article{c01b5d280fda4344b2877b697649c305,

title = "Recent advances in metabolomics analysis for early drug development",

abstract = "The pharmaceutical industry adapted proteomics and other 'omics technologies for drug research early following their initial introduction. Although metabolomics lacked behind in this development, it has now become an accepted and widely applied approach in early drug development. Over the past few decades, metabolomics has evolved from a pure exploratory tool to a more mature and quantitative biochemical technology. Several metabolomics-based platforms are now applied during the early phases of drug discovery. Metabolomics analysis assists in the definition of the physiological response and target engagement (TE) markers as well as elucidation of the mode of action (MoA) of drug candidates under investigation. In this review, we highlight recent examples and novel developments of metabolomics analyses applied during early drug development.",

author = "Alarc{\'o}n, {Juan Carlos} and Sarantos Kostidis and Alejandro Ondo-M{\'e}ndez and Martin Giera",

year = "2022",

month = feb,

day = "24",

doi = "10.1016/j.drudis.2022.02.018",

language = "English (US)",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Recent advances in metabolomics analysis for early drug development

AU - Alarcón, Juan Carlos

AU - Kostidis, Sarantos

AU - Ondo-Méndez, Alejandro

AU - Giera, Martin

PY - 2022/2/24

Y1 - 2022/2/24

N2 - The pharmaceutical industry adapted proteomics and other 'omics technologies for drug research early following their initial introduction. Although metabolomics lacked behind in this development, it has now become an accepted and widely applied approach in early drug development. Over the past few decades, metabolomics has evolved from a pure exploratory tool to a more mature and quantitative biochemical technology. Several metabolomics-based platforms are now applied during the early phases of drug discovery. Metabolomics analysis assists in the definition of the physiological response and target engagement (TE) markers as well as elucidation of the mode of action (MoA) of drug candidates under investigation. In this review, we highlight recent examples and novel developments of metabolomics analyses applied during early drug development.

AB - The pharmaceutical industry adapted proteomics and other 'omics technologies for drug research early following their initial introduction. Although metabolomics lacked behind in this development, it has now become an accepted and widely applied approach in early drug development. Over the past few decades, metabolomics has evolved from a pure exploratory tool to a more mature and quantitative biochemical technology. Several metabolomics-based platforms are now applied during the early phases of drug discovery. Metabolomics analysis assists in the definition of the physiological response and target engagement (TE) markers as well as elucidation of the mode of action (MoA) of drug candidates under investigation. In this review, we highlight recent examples and novel developments of metabolomics analyses applied during early drug development.

U2 - 10.1016/j.drudis.2022.02.018

DO - 10.1016/j.drudis.2022.02.018

M3 - Article

C2 - 35218927

SN - 1359-6446

JO - Drug Discovery Today

JF - Drug Discovery Today

ER -

Recent advances in metabolomics analysis for early drug development

Resumen

Áreas temáticas de ASJC Scopus

ODS de las Naciones Unidas

Acceder al documento

Huella

Citar esto